Intuitive Surgical, Inc designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Its da Vinci Surgical System transforms the surgeon's natural hand movements outside the body into corresponding micro-movements inside the patient's body. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone408-523-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.72 billion
Profitability
Miscellaneous
Employees5,527
Next Earnings Date1/23/2020 (Confirmed)
OptionableOptionable
Intuitive Surgical (NASDAQ:ISRG) Frequently Asked Questions
What is Intuitive Surgical's stock symbol?
Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."
When did Intuitive Surgical's stock split? How did Intuitive Surgical's stock split work?
Shares of Intuitive Surgical split before market open on Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly minted shares were issued to shareholders after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split.
How were Intuitive Surgical's earnings last quarter?
Intuitive Surgical, Inc. (NASDAQ:ISRG) announced its quarterly earnings results on Thursday, October, 17th. The medical equipment provider reported $3.43 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.99 by $0.44. The medical equipment provider had revenue of $1.13 billion for the quarter, compared to analysts' expectations of $1.06 billion. Intuitive Surgical had a net margin of 30.94% and a return on equity of 18.26%. The business's revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.83 earnings per share. View Intuitive Surgical's Earnings History.
When is Intuitive Surgical's next earnings date?
How can I listen to Intuitive Surgical's earnings call?
Intuitive Surgical will be holding an earnings conference call on Thursday, January 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Intuitive Surgical issued on next quarter's earnings?
Intuitive Surgical issued an update on its fourth quarter 2019
After-Hours earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.278-1.278 billion, compared to the consensus revenue estimate of $1.22 billion.
What price target have analysts set for ISRG?
15 brokers have issued 12 month price objectives for Intuitive Surgical's stock. Their forecasts range from $375.00 to $690.00. On average, they anticipate Intuitive Surgical's share price to reach $605.67 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price. View Analyst Price Targets for Intuitive Surgical.
What is the consensus analysts' recommendation for Intuitive Surgical?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intuitive Surgical.
What are Wall Street analysts saying about Intuitive Surgical stock?
Here are some recent quotes from research analysts about Intuitive Surgical stock:
- 1. According to Zacks Investment Research, "Intuitive Surgical ended the third quarter on a solid note. The flagship da Vinci procedures recorded solid growth in the quarter which drove the core Instrument & Accessories arm. In fact, management continues to expect strong procedure growth in 2019. The company looks to accelerate its business in China, which saw a solid third quarter as well. Overall international sales surged in the quarter. Expansion in gross margin is an added positive. The stock has outperformed the industry in a year’s time. On the flip side, contraction in operating margin is worrisome. Additionally, the da Vinci system is in the early stages of adoption in some of the markets outside the United States, which is likely to impede placements. Intense competition in the global MedTech space is concerning as well." (11/21/2019)
- 2. BTIG Research analysts commented, "like we previewed, ISRG posted a healthy beat on procedures and system units placed but reported a slight miss on sales (increased leases) and opex came in near the top end of guidance, causing EPS to miss. We understand the benefits of offering several routes to system acquisition and the leases do not bother us. Getting more systems out there and surgeons trained before any significant competition makes sense. The continued increased spending is a concern. While we gather robotics is in the early days, the increased spending started a few years ago and what was initially discussed as a one- or two-year plan has become now at least a three- or four-year plan that seems like it may last a long time. With guidance revised to a 24-28% y/y increase vs the initial 20-28%, investors may pause." (4/21/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating on shares of ISRG and maintain our PT of $620. ISRG reported 4Q18 results consistent with its preliminary announcement (1/9). ISRG delivered 19% procedure growth for 4Q18, largely driven by US general surgery and worldwide urology. ISRG reiterated its procedure growth guidance (13-17%), however we expect initial guidance to prove conservative as it has over the past several years. Management plans to increase opex by 20-28% in 2019, which comes as a surprise. We expect investors to have an initial negative reaction to the expected significant increase in spending, but we think the investments will fuel future top-line growth and accelerate ISRG’s pipeline." (1/25/2019)
Has Intuitive Surgical been receiving favorable news coverage?
Press coverage about ISRG stock has been trending extremely negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intuitive Surgical earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Intuitive Surgical.
Are investors shorting Intuitive Surgical?
Intuitive Surgical saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,840,000 shares, an increase of 20.3% from the December 15th total of 1,530,000 shares. Based on an average daily volume of 595,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 1.6% of the company's stock are sold short. View Intuitive Surgical's Current Options Chain.
Who are some of Intuitive Surgical's key competitors?
Some companies that are related to Intuitive Surgical include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).
What other stocks do shareholders of Intuitive Surgical own?
Who are Intuitive Surgical's key executives?
Intuitive Surgical's management team includes the folowing people:
- Dr. Gary S. Guthart, CEO, Pres & Director (Age 53)
- Mr. Marshall L. Mohr, Exec. VP & CFO (Age 63)
- Mr. Salvatore J. Brogna, Exec. VP & COO (Age 64)
- Mr. David J. Rosa, Exec. VP & Chief Bus. Officer (Age 51)
- Dr. Myriam J. Curet McAdams, Exec. VP & Chief Medical Officer (Age 62)
Who are Intuitive Surgical's major shareholders?
Intuitive Surgical's stock is owned by many different of retail and institutional investors. Top institutional investors include Johanson Financial Advisors Inc. (0.38%), Calamos Advisors LLC (0.06%), Gateway Investment Advisers LLC (0.06%), Peregrine Capital Management LLC (0.04%), Commerzbank Aktiengesellschaft FI (0.04%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Intuitive Surgical stock include Amal M Johnson, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman, Neeraj Gupta, Reiter Kara Andersen and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.
Which institutional investors are selling Intuitive Surgical stock?
ISRG stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Gateway Investment Advisers LLC, State of Alaska Department of Revenue, Arlington Financial Advisors LLC, Manning & Napier Group LLC and IFM Investors Pty Ltd. Company insiders that have sold Intuitive Surgical company stock in the last year include Curet Myriam, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Rubash, Marshall Mohr, Michael A Friedman, Neeraj Gupta, Reiter Kara Andersen and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.
Which institutional investors are buying Intuitive Surgical stock?
ISRG stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Rhenman & Partners Asset Management AB, Verde Servicos Internacionais S.A., Commerzbank Aktiengesellschaft FI, Alpha Cubed Investments LLC, DNB Asset Management AS, Sciencast Management LP and Central Bank & Trust Co.. View Insider Buying and Selling for Intuitive Surgical.
How do I buy shares of Intuitive Surgical?
Shares of ISRG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Intuitive Surgical's stock price today?
One share of ISRG stock can currently be purchased for approximately $601.66.
How big of a company is Intuitive Surgical?
Intuitive Surgical has a market capitalization of $69.53 billion and generates $3.72 billion in revenue each year. The medical equipment provider earns $1.13 billion in net income (profit) each year or $9.49 on an earnings per share basis. Intuitive Surgical employs 5,527 workers across the globe.View Additional Information About Intuitive Surgical.
What is Intuitive Surgical's official website?
How can I contact Intuitive Surgical?
Intuitive Surgical's mailing address is 1020 KIFER ROAD, SUNNYVALE CA, 94086. The medical equipment provider can be reached via phone at 408-523-2100 or via email at [email protected]
MarketBeat Community Rating for Intuitive Surgical (NASDAQ ISRG)
MarketBeat's community ratings are surveys of what our community members think about Intuitive Surgical and other stocks. Vote "Outperform" if you believe ISRG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISRG will underperform the S&P 500 over the long term. You may vote once every thirty days.
